AQR Capital Management
STOK icon

AQR Capital Management’s Stoke Therapeutics STOK Stock Holding History

AQR Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Buy
46,459
+16,992
+58% +$557K ﹤0.01% 2538
2025
Q4 		$935K Buy
29,467
+354
+1% +$10.6K ﹤0.01% 2597
2025
Q3 		$684K Sell
29,113
-25,705
-47% -$440K ﹤0.01% 2651
2025
Q2 		$622K Buy
54,818
+41,971
+327% +$399K ﹤0.01% 2484
2025
Q1 		$85.4K Sell
12,847
-10,772
-46% -$100K ﹤0.01% 3036
2024
Q4 		$261K Sell
23,619
-51,470
-69% -$632K ﹤0.01% 2565
2024
Q3 		$923K Buy
+75,089
New +$1.06M ﹤0.01% 1889

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AQR Capital Management's STOK Position: Q1 2026 in Review

AQR Capital Management increased its Stoke Therapeutics (STOK) stake by 58% in Q1 2026, buying an estimated $557K and bringing the position to 46,459 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2538.

AQR Capital Management first reported a position in STOK in Q3 2024 and has held it in 7 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • AQR Capital Management held 46,459 shares of Stoke Therapeutics worth $1.51M as of Q1 2026.
  • AQR Capital Management bought 16,992 Stoke Therapeutics shares in Q1 2026, an estimated $557K.
  • Stoke Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2538 holding.
  • AQR Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.